Compare VERA & PHIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VERA | PHIN |
|---|---|---|
| Founded | 2016 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.8B |
| IPO Year | 2021 | 2023 |
| Metric | VERA | PHIN |
|---|---|---|
| Price | $37.16 | $79.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $81.30 | $70.00 |
| AVG Volume (30 Days) | ★ 2.5M | 426.5K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 1.66% |
| EPS Growth | N/A | ★ 84.09 |
| EPS | N/A | ★ 0.96 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.35 |
| Revenue Next Year | $472.48 | $2.29 |
| P/E Ratio | ★ N/A | $80.41 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.07 | $47.83 |
| 52 Week High | $56.05 | $86.94 |
| Indicator | VERA | PHIN |
|---|---|---|
| Relative Strength Index (RSI) | 42.34 | 50.62 |
| Support Level | $32.48 | $78.25 |
| Resistance Level | $38.59 | $80.28 |
| Average True Range (ATR) | 2.75 | 2.82 |
| MACD | -0.78 | -0.10 |
| Stochastic Oscillator | 11.67 | 67.09 |
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Phinia Inc is engaged in the development, design, and manufacture of integrated components and systems that optimize performance, increase efficiency, and reduce emissions in combustion and hybrid propulsion for commercial vehicles, industrial applications, and light vehicles. Its product portfolio includes alternative fuel systems, fuel delivery modules, evaporative canisters, diesel fuel injection systems, electrical systems, hydrogen solutions, associated software, and others. The company's reportable segments are; the Fuel Systems segment, which derives key revenue, and the Aftermarket segment. Geographically, it generates maximum revenue from the United States and the rest from the United Kingdom, China, Poland, Romania, Brazil, and other regions.